FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310106585> ?p ?o ?g. }

• W4310106585 endingPage "12132" @default.
• W4310106585 startingPage "12130" @default.
• W4310106585 abstract "Introduction B-cell non-Hodgkin lymphoma (NHL) is the most common hematological malignancy encompassing heterogenous subtypes (Dotan et al., PT 2010). Rituximab (R) has changed the treatment landscape of NHL; approvals of rituximab biosimilars have improved access to and the affordability of this treatment (Mohammed et al., J Blood Med 2019). HLX01 is the first rituximab biosimilar approved for the treatment of NHL and chronic lymphocytic leukemia in China. In a Phase 3 trial enrolling patients with diffuse large B-cell lymphoma (DLBCL), HLX01 demonstrated bioequivalence to reference rituximab in terms of efficacy and safety (Shi et al., J Hematol Oncol 2020). The current study is an ongoing, observational study with the objectives of characterizing the distribution of B-cell NHL subtypes in patients receiving HLX01 and assessing the effectiveness and safety of HLX01 in patients with B-cell NHL subtypes in a real-world setting in China. Methods This multicenter, real-world study enrolled adult patients with pathologically confirmed B-cell NHL subtypes at 40 hospitals in China. HLX01 (either as monotherapy or combination therapy) was recommended, but the selection of treatment regimen was at the investigator's discretion. The primary endpoint was the distribution of B-cell NHL subtypes in patients receiving HLX01. Secondary endpoints were objective response rate (ORR) and complete response (CR) rate in patients with B-cell NHL and progression-free survival (PFS) and overall survival (OS) rates at 1, 3, and 5 years in subgroups categorized by disease characteristics. Response was evaluated every 6 weeks until disease progression or end of treatment, using the Lugano 2014 criteria. After treatment, disease and survival status were followed up every 2 months. Safety was monitored until 1 month after treatment completion. Here, we report results from baseline to 1-year follow-up. Results Between April 2020 and June 2021, 2053 patients were enrolled; of these patients, 1898 had evaluable efficacy data (full analysis set [FAS]) and 1878 had completed ≥ 5 treatment cycles (per-protocol set [PPS]). Overall, the most common subtype was DLBCL (1231/2053, 60.0%), followed by follicular lymphoma (293/2053, 14.3% [Table 1]). Among patients in the FAS, R-CHOP was the most commonly used regimen (1006/1898, 53.0%). Other regimens included BR (175/1898, 9.2%), R monotherapy (150/1898, 7.9%), R2 (63/1898, 3.3%), R-EPOCH (56/1898, 2.95%), DA-R-EPOCH (48/1898, 2.5%), R-DA-EDOCH (18/1898, 0.95%), R-EDOCH (11/1898, 0.58%), and others (371/1898, 19.5%). In the FAS, 868 (45.7%) patients had CR/CRu (CR + unconfirmed CR) and 883 (46.5%) had partial response, contributing to an ORR of 92.3%; in the PPS, the ORR was 93.2%. In 215 patients with evaluable OS and PFS data, median OS and PFS were not reached, and 1-year OS and PFS rates were 90.7% and 74.4%, respectively. In patients with DLBCL in the FAS, 519 (45.5%) had CR/CRu and the ORR was 91.8%. In 139 evaluable patients with DLBCL, 1-year OS and PFS rates were 91.3% and 75.6%, respectively. The ORRs in most subtypes exceeded 90% (Table 2). Among all patients, 423 (20.6%) experienced adverse events (AEs), most of which were grade 1 or 2 in severity. The most common AEs were decreased white blood cell count (3.9%), decreased neutrophil count (3.5%), and nausea/vomiting (3.3%). Conclusions DLBCL is the most common subtype in HLX01-treated patients with B-cell NHL in China. HLX01 showed clinical benefits with favorable safety profiles in patients with B-cell NHL subtypes in a real-world setting. Clinical trial identification: ChiCTR2000032263. Research funding: None. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310106585 created "2022-11-30" @default.
• W4310106585 creator A5000048962 @default.
• W4310106585 creator A5004661714 @default.
• W4310106585 creator A5005882410 @default.
• W4310106585 creator A5029493707 @default.
• W4310106585 creator A5038163809 @default.
• W4310106585 creator A5044110703 @default.
• W4310106585 creator A5045048134 @default.
• W4310106585 creator A5053416505 @default.
• W4310106585 creator A5057287134 @default.
• W4310106585 creator A5061006889 @default.
• W4310106585 creator A5068306478 @default.
• W4310106585 creator A5082197639 @default.
• W4310106585 creator A5083531621 @default.
• W4310106585 creator A5091908162 @default.
• W4310106585 date "2022-11-15" @default.
• W4310106585 modified "2023-09-27" @default.
• W4310106585 title "Disease Characteristics and Treatment Outcomes with HLX01: A Real-World Study in Patients with B-Cell Non-Hodgkin Lymphoma in China" @default.
• W4310106585 doi "https://doi.org/10.1182/blood-2022-166137" @default.
• W4310106585 hasPublicationYear "2022" @default.
• W4310106585 type Work @default.
• W4310106585 citedByCount "0" @default.
• W4310106585 crossrefType "journal-article" @default.
• W4310106585 hasAuthorship W4310106585A5000048962 @default.
• W4310106585 hasAuthorship W4310106585A5004661714 @default.
• W4310106585 hasAuthorship W4310106585A5005882410 @default.
• W4310106585 hasAuthorship W4310106585A5029493707 @default.
• W4310106585 hasAuthorship W4310106585A5038163809 @default.
• W4310106585 hasAuthorship W4310106585A5044110703 @default.
• W4310106585 hasAuthorship W4310106585A5045048134 @default.
• W4310106585 hasAuthorship W4310106585A5053416505 @default.
• W4310106585 hasAuthorship W4310106585A5057287134 @default.
• W4310106585 hasAuthorship W4310106585A5061006889 @default.
• W4310106585 hasAuthorship W4310106585A5068306478 @default.
• W4310106585 hasAuthorship W4310106585A5082197639 @default.
• W4310106585 hasAuthorship W4310106585A5083531621 @default.
• W4310106585 hasAuthorship W4310106585A5091908162 @default.
• W4310106585 hasConcept C126322002 @default.
• W4310106585 hasConcept C143998085 @default.
• W4310106585 hasConcept C203092338 @default.
• W4310106585 hasConcept C2778559949 @default.
• W4310106585 hasConcept C2779338263 @default.
• W4310106585 hasConcept C2780653079 @default.
• W4310106585 hasConcept C2781413609 @default.
• W4310106585 hasConcept C535046627 @default.
• W4310106585 hasConcept C71924100 @default.
• W4310106585 hasConceptScore W4310106585C126322002 @default.
• W4310106585 hasConceptScore W4310106585C143998085 @default.
• W4310106585 hasConceptScore W4310106585C203092338 @default.
• W4310106585 hasConceptScore W4310106585C2778559949 @default.
• W4310106585 hasConceptScore W4310106585C2779338263 @default.
• W4310106585 hasConceptScore W4310106585C2780653079 @default.
• W4310106585 hasConceptScore W4310106585C2781413609 @default.
• W4310106585 hasConceptScore W4310106585C535046627 @default.
• W4310106585 hasConceptScore W4310106585C71924100 @default.
• W4310106585 hasIssue "Supplement 1" @default.
• W4310106585 hasLocation W43101065851 @default.
• W4310106585 hasOpenAccess W4310106585 @default.
• W4310106585 hasPrimaryLocation W43101065851 @default.
• W4310106585 hasRelatedWork W1969362652 @default.
• W4310106585 hasRelatedWork W1996279342 @default.
• W4310106585 hasRelatedWork W2125885683 @default.
• W4310106585 hasRelatedWork W2390430401 @default.
• W4310106585 hasRelatedWork W2805808559 @default.
• W4310106585 hasRelatedWork W2915014687 @default.
• W4310106585 hasRelatedWork W2938747763 @default.
• W4310106585 hasRelatedWork W2979864420 @default.
• W4310106585 hasRelatedWork W3049596273 @default.
• W4310106585 hasRelatedWork W79716904 @default.
• W4310106585 hasVolume "140" @default.
• W4310106585 isParatext "false" @default.
• W4310106585 isRetracted "false" @default.
• W4310106585 workType "article" @default.